Biopharmaceutical Analysis & Statistics, May 2015 (p7)

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Publishers

All regions

181-210 of about 1 900 reports

Purchase Reports From Reputable Market Research Publishers

Anti-CD38 Antibody -Pipeline Insights, 2015

Anti-CD38 Antibody -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Anti-CD38 Antibody- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Anti-CD38 Antibody. The main objective of this report to track competito ...

  • Industries : Biopharmaceutical
Anti-CD105 Antibody -Pipeline Insights, 2015

Anti-CD105 Antibody -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Anti-CD105 Antibody- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Anti-CD105 Antibody. The main objective of this report to track ...

  • Industries : Biopharmaceutical
Anti-CD4 Antibody -Pipeline Insights, 2015

Anti-CD4 Antibody -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Anti-CD4 Antibody- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Anti-CD4 Antibody. The main objective of this report to track competito ...

  • Industries : Biopharmaceutical
ATP Binding Cassette Sub Family B member 1 (ABCB1 or P-Glycoprotein or P-gp) Inhibitors -Pipeline Insights, 2015

ATP Binding Cassette Sub Family B member 1 (ABCB1 or P-Glycoprotein or P-gp) Inhibitors -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, ATP Binding Cassette Sub Family B member 1 (ABCB1 or P-Glycoprotein or P-gp) Inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across ...

  • Industries : Biopharmaceutical
Factor IX A Inhibitors -Pipeline Insights, 2015

Factor IX A Inhibitors -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Factor IX A Inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Factor IX A Inhibitors. The main objective of this report to ...

  • Industries : Biopharmaceutical
Anti-CS1 Antibody -Pipeline Insights, 2015

Anti-CS1 Antibody -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Anti-CS1 Antibody- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Anti-CS1 Antibody. The main objective of this report to track competito ...

  • Industries : Biopharmaceutical
Anti-CD3 Antibody -Pipeline Insights, 2015

Anti-CD3 Antibody -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Anti-CD3 Antibody- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Anti-CD3 Antibody. The main objective of this report to track competito ...

  • Industries : Biopharmaceutical
Anti-CD22 Antibody -Pipeline Insights, 2015

Anti-CD22 Antibody -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Anti-CD22 Antibody- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Anti-CD22 Antibody. The main objective of this report to track competito ...

  • Industries : Biopharmaceutical
Anti-CD279 (PD-1) Antibody -Pipeline Insights, 2015

Anti-CD279 (PD-1) Antibody -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Anti-CD279 (PD-1) Antibody- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Anti-CD279 (PD-1) Antibody. The main objective of this report ...

  • Industries : Biopharmaceutical
Alpha2beta1 Integrin Antagonists (Very Late Antigen 2 (VLA-2) -Pipeline Insights, 2015

Alpha2beta1 Integrin Antagonists (Very Late Antigen 2 (VLA-2) -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Alpha2beta1 Integrin Antagonists (Very Late Antigen 2 (VLA-2)- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Alpha2beta1 Integrin Antagonists ...

  • Industries : Biopharmaceutical
Anti-CD40 Antibody -Pipeline Insights, 2015

Anti-CD40 Antibody -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Anti-CD40 Antibody- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Anti-CD40 Antibody. The main objective of this report to track competito ...

  • Industries : Biopharmaceutical
Epithelial Cell Adhesion Molecule (EpCAM or CD326) Inhibitors -Pipeline Insights, 2015

Epithelial Cell Adhesion Molecule (EpCAM or CD326) Inhibitors -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Epithelial Cell Adhesion Molecule (EpCAM or CD326) Inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Epithelial Cell Adhesion ...

  • Industries : Biopharmaceutical
Insulin Like Growth Factor 2 (IGF-2) Inhibitors -Pipeline Insights, 2015

Insulin Like Growth Factor 2 (IGF-2) Inhibitors -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Insulin Like Growth Factor 2 (IGF-2) Inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Insulin Like Growth Factor 2 (IGF-2) ...

  • Industries : Biopharmaceutical
Tumor Necrosis Factor (TNF) Agonists -Pipeline Insights, 2015

Tumor Necrosis Factor (TNF) Agonists -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Tumor Necrosis Factor (TNF) Agonists- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Tumor Necrosis Factor (TNF) Agonists. The main ...

  • Industries : Biopharmaceutical
Glucagon Receptor Antagonists -Pipeline Insights, 2015

Glucagon Receptor Antagonists -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Glucagon Receptor Antagonists- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Glucagon Receptor Antagonists. The main objective of this ...

  • Industries : Biopharmaceutical
Glucagon-Like Peptide (GLP) Agonists -Pipeline Insights, 2015

Glucagon-Like Peptide (GLP) Agonists -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Glucagon-Like Peptide (GLP) Agonists- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Glucagon-Like Peptide (GLP) Agonists. The main ...

  • Industries : Biopharmaceutical
Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors -Pipeline Insights, 2015

Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors. ...

  • Industries : Biopharmaceutical
Anti-CD95 Antibody -Pipeline Insights, 2015

Anti-CD95 Antibody -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Anti-CD95 Antibody- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Anti-CD95 Antibody. The main objective of this report to track competito ...

  • Industries : Biopharmaceutical
Anti-CD80 Antibody -Pipeline Insights, 2015

Anti-CD80 Antibody -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Anti-CD80 Antibody- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Anti-CD80 Antibody. The main objective of this report to track competito ...

  • Industries : Biopharmaceutical
Tumor Necrosis Factor (TNF) Inhibitors -Pipeline Insights, 2015

Tumor Necrosis Factor (TNF) Inhibitors -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Tumor Necrosis Factor (TNF) Inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Tumor Necrosis Factor (TNF) Inhibitors. The main ...

  • Industries : Biopharmaceutical
Tumor Necrosis Factor Alpha (TNF-a) Agonists -Pipeline Insights, 2015

Tumor Necrosis Factor Alpha (TNF-a) Agonists -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Tumor Necrosis Factor Alpha (TNF-a) Agonists- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Tumor Necrosis Factor Alpha (TNF-a) Agonists. ...

  • Industries : Biopharmaceutical
Anti-CD33 Antibody -Pipeline Insights, 2015

Anti-CD33 Antibody -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Anti-CD33 Antibody- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Anti-CD33 Antibody. The main objective of this report to track competito ...

  • Industries : Biopharmaceutical
Lymphocyte Function-Associated Antigen 1 (LFA-1) Antagonist -Pipeline Insights, 2015

Lymphocyte Function-Associated Antigen 1 (LFA-1) Antagonist -Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, Lymphocyte Function-Associated Antigen 1 (LFA-1) Antagonist- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Lymphocyte Function-Associated ...

  • Industries : Biological Therapy, Biopharmaceutical, Biotechnology
Anti-Infective Drug News 11 MAY 2015

Anti-Infective Drug News 11 MAY 2015

  • $ 1 114
  • Industry report
  • May 2015
  • by Espicom Business Intelligence

Industry Trend Analysis - GSK's Shingles Vaccine To Erode Sales Of Merck's Zostavax Industry Brief - FDA Accepts NDA Filing For AuriPro Industry Brief - Single-Dose Dalvance Meets Primary/Secondary Endpoints ...

  • Industries : Drug and Medication, Biopharmaceutical
  • Countries : Europe, India, United States
Anti-Infective Drug News 27 APRIL 2015

Anti-Infective Drug News 27 APRIL 2015

  • $ 1 114
  • Industry report
  • April 2015
  • by Espicom Business Intelligence

Industry Trend Analysis - Sovaldi Pricing To Remain An Issue Despite Groundbreaking Programme Industry Brief - Actavis' Avycaz Available In US Industry Brief - Milestone Triggered As Evolva Completes Transfe ...

  • Industries : Drug and Medication, Biopharmaceutical
  • Countries : Japan
Anti-Infective Drug News 13 APRIL 2015

Anti-Infective Drug News 13 APRIL 2015

  • $ 1 114
  • Industry report
  • April 2015
  • by Espicom Business Intelligence

Industry Trend Analysis - Viable Generic Sofosbuvir Market Will Increase Pricing Pressures For Gilead Industry Brief - FDA Approves Sanofi's Quadracel DTaP-IPV Vaccine For Children Aged Four Through Six ...

  • Industries : Drug and Medication, Biopharmaceutical
  • Countries : Japan
Biosimilars Business Review Q1 2015

Biosimilars Business Review Q1 2015

  • $ 1 114
  • Industry report
  • March 2015
  • by Espicom Business Intelligence

Industry Trend Analysis - Zarxio's Approval Will See Focus Shift To Battle For Market Acceptance Industry Brief - Apotex' Pegfilgrastim Biosimilar Accepted By FDA Industry Brief - FDA Approves Teva's Filgrastim ...

  • Industries : Biopharmaceutical
  • Countries : Europe
Anti-Infective Drug News 23 MARCH 2015

Anti-Infective Drug News 23 MARCH 2015

  • $ 1 114
  • Industry report
  • March 2015
  • by Espicom Business Intelligence

Industry Trend Analysis - Cresemba's Double Approval Will Make It Standard-Of-Care For Fungal Disease Industry Brief - Prevenar 13 CAPiTA Trial Meets Primary/Secondary Objectives Industry Brief - Pfenex/Glide ...

  • Industries : Drug and Medication, Biopharmaceutical
  • Countries : China
Anti-Infective Drug News 09 MARCH 2015

Anti-Infective Drug News 09 MARCH 2015

  • $ 1 114
  • Industry report
  • March 2015
  • by Espicom Business Intelligence

Industry Trend Analysis - Avycaz Approval Is First Of Many Branded Blockbusters Expected For Actavis Industry Brief - IBT's Drug Candidate Gains EU Orphan Drug Designation For NEC Industry Brief - EC Approves ...

  • Industries : Drug and Medication
World Generic Markets 02 MARCH 2015

World Generic Markets 02 MARCH 2015

  • $ 1 114
  • Industry report
  • March 2015
  • by Espicom Business Intelligence

Industry Trend Analysis - Roche Most At Risk From Upcoming Biosimilar Oncology Market Industry Brief - Merck Provides MPP With Paediatric Raltegravir Licence Industry Brief - Sucampo/R-Tech Settlement ...

  • Industries : Biopharmaceutical, Drug and Medication
  • Countries : Europe

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.